Details of the Drug Combinations

General Information of This Drug (ID: DMW8N72)

Drug Name

XL-228 DMW8N72

Synonyms

XL-228; 898280-07-4; XL228; UNII-33M2XSK003; 33M2XSK003; 4-N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-N-[(3-propan-2-yl-1,2-oxazol-5-yl)methyl]pyrimidine-2,4-diamine; SCHEMBL11342904; CHEMBL3545085; AOB5553; EX-A1596; BCP08143; XL 228; ZINC203005669; AKOS030526975; CS-1648; NCGC00378978-05; SC-95574; AS-16897; HY-15749; AC-30228; 2,4-Pyrimidinediamine, N(sup 4)-(5-cyclopropyl-1H-pyrazol-3-yl)-N(sup 2)-((3-(1-methylethyl)-5-isoxazolyl)methyl)-6-(4-methyl-1-piperazinyl)-; KB-303240

Indication

Disease Entry	ICD 11	Status	REF
leukaemia	2A60-2B33	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
XL-228 + Panobinostat	DCBWHCE	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00526838) Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies. U.S. National Institutes of Health.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.